Prevalence and risk factors associated with rifampicin-induced cholestasis jaundice among tuberculosis patients in high-incidence setting: A retrospective cohort study
Rifampicin-induced cholestatic jaundice was observed in 1.52% of TB patients. Older age (≥60 years) and low BMI (<18.5 kg/m<sup>2</sup>) were identified as key risk factors.Early liver monitoring is essential in high-risk groups. Most patients tolerated rifampicin rechallenge, supporting individualized, risk-based management to ensure safe and effective TB treatment.
Authors
- Piyapan Prueksapanich (ORCID: https://orcid.org/0000-0001-5811-0120)
- Gompol Suwanpimolkul (ORCID: https://orcid.org/0000-0002-5199-7440)
- Manunchaya Sintusuwan
Institutions
- Thai Red Cross Society (TH)
- Chulalongkorn University (TH)
- King Chulalongkorn Memorial Hospital (TH)
Publication Details
- Journal
- Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Published
- 2026-02-14
- DOI
- https://doi.org/10.1016/j.jctube.2026.100590
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00